Cargando…
Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentration
Double mutant heat-labile toxin (dmLT) is a novel vaccine adjuvant under development with several different vaccine candidates. Studies using existing dmLT adjuvant stocks require significant dilution to achieve a clinically relevant dose. This dilution leads to wastage of the adjuvant. This manuscr...
Autores principales: | Estrada, Marcus R., Bzami, Anan, Norton, Elizabeth B., White, Jessica A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932622/ https://www.ncbi.nlm.nih.gov/pubmed/36658044 http://dx.doi.org/10.1016/j.vaccine.2023.01.005 |
Ejemplares similares
-
The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT
por: Clements, John D., et al.
Publicado: (2018) -
Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients
por: Stone, Addison E., et al.
Publicado: (2023) -
Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant
por: Toprani, Vishal M., et al.
Publicado: (2017) -
dmLT Adjuvant Enhances Cytokine Responses to T Cell Stimuli, Whole Cell Vaccine Antigens and Lipopolysaccharide in Both Adults and Infants
por: Akhtar, Marjahan, et al.
Publicado: (2021) -
Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge
por: Stone, Addison E., et al.
Publicado: (2021)